Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Sold by Bridge City Capital LLC

Bridge City Capital LLC lessened its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 70,095 shares of the company’s stock after selling 984 shares during the quarter. Bridge City Capital LLC owned about 0.15% of Amphastar Pharmaceuticals worth $2,603,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Smartleaf Asset Management LLC increased its stake in Amphastar Pharmaceuticals by 222.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock valued at $26,000 after buying an additional 493 shares during the period. Parkside Financial Bank & Trust increased its stake in shares of Amphastar Pharmaceuticals by 806.5% during the fourth quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock valued at $36,000 after acquiring an additional 871 shares during the period. Point72 Asia Singapore Pte. Ltd. raised its holdings in Amphastar Pharmaceuticals by 53.4% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after purchasing an additional 398 shares in the last quarter. TD Private Client Wealth LLC lifted its position in Amphastar Pharmaceuticals by 22.7% in the fourth quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company’s stock worth $78,000 after purchasing an additional 388 shares during the period. Finally, KBC Group NV boosted its stake in Amphastar Pharmaceuticals by 43.1% during the 4th quarter. KBC Group NV now owns 2,159 shares of the company’s stock valued at $80,000 after purchasing an additional 650 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Piper Sandler dropped their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research note on Friday.

Amphastar Pharmaceuticals Trading Up 1.4 %

Shares of NASDAQ:AMPH opened at $28.29 on Friday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of 9.43, a PEG ratio of 2.19 and a beta of 0.77. Amphastar Pharmaceuticals, Inc. has a 1-year low of $25.89 and a 1-year high of $53.96. The company has a 50 day moving average price of $31.91 and a 200 day moving average price of $40.52.

Insider Activity

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the business’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the sale, the chief financial officer now owns 97,363 shares in the company, valued at approximately $2,681,377.02. The trade was a 4.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.